Effect of canagliflozin on urinary albumin excretion in Japanese patients with type 2 diabetes mellitus and microalbuminuria: A pilot study

Diabetes Technology and Therapeutics

Volumn 20, Issue 10, 2018, Pages 681-688

  Osonoi, Takeshi ^a   Gouda, Maki ^b   Kubo, Mamiko ^b   Arakawa, Kenji ^b   Hashimoto, Toshio ^b   Abe, Masanori ^c  

^a Naka Kinen Clinic   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Albuminuria; Canagliflozin; Nephropathy; Renoprotective effect; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; BIOLOGICAL MARKER; CANAGLIFLOZIN; ERYTHROPOIETIN; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG EFFECT; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FLUID INTAKE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; JAPANESE (PEOPLE); KIDNEY INJURY; MALE; MICROALBUMINURIA; MYALGIA; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY EXCRETION; URINE LEVEL; URINE SAMPLING; URINE VOLUME; ALBUMINURIA; ANALYSIS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BODY WEIGHT; DIABETIC NEPHROPATHY; KIDNEY FUNCTION TEST; MIDDLE AGED; URINE; YOUNG ADULT;

ADULT; AGED; ALBUMINURIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PILOT PROJECTS; YOUNG ADULT;

EID: 85054095310     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2018.0169     Document Type: Article

References (49)

1. Shahbazian H, Rezaii I: Diabetic kidney disease; review of the current knowledge. J Renal Inj Prev 2013;2:73-80.
2. Tomino Y, Gohda T: The prevalence and management of diabetic nephropathy in Asia. Kidney Dis (Basel) 2015;1: 52-60.
3. Ninomiya T, Perkovic V, de Galan BE, et al.: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20: 1813-1821.
4. Katayama S, Moriya T, Tanaka S, et al.: Low transition rate from normo-and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study ( JDCS). Diabetologia 2011;54:1025-1031.
5. Cowie CC, Port FK, Wolfe RA, et al.: Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074-1079.
6. Stephens GW, Gillaspy JA, Clyne D, et al.: Racial differences in the incidence of end-stage renal disease in types I and II diabetes mellitus. Am J Kidney Dis 1990;15:562-567.
7. Chandie Shaw PK, Baboe F, van Es LA, et al.: South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. Diabetes Care 2006;29:1383-1385.
8. Parving HH, Lewis JB, Ravid M, et al.: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006;69: 2057-2063.
9. United States Renal Data System: 2017 ADR Reference Tables. https://www.usrds.org/reference.aspx (accessed June 19, 2018).
10. Masakane I, Nakai S, Ogata S, et al.: An overview of regular dialysis treatment in Japan (as of 31 December 2013). Ther Apher Dial 2015;19:540-574.
11. Mudaliar S, Polidori D, Zambrowicz B, Henry RR: Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 2015;38:2344-2353.
12. Inagaki N, Kondo K, Yoshinari T, et al.: Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013;15:1136-1145.
13. Inagaki N, Kondo K, Yoshinari T, et al.: Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebocontrolled, phase III study. Expert Opin Pharmacother 2014;15:1501-1515.
14. Polidori D, Mari A, Ferrannini E: Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 2014;57:891-901.
15. Inagaki N, Kondo K, Yoshinari T, Kuki H: Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52-week open-label study. J Diabetes Investig 2015;6:210-218.
16. Cherney DZ, Perkins BA, Soleymanlou N, et al.: Sodium glucose cotransport-2 inhibition and intrarenalRAS activity in people with type 1 diabetes. Kidney Int 2014;86:1057-1058.
17. Novikov A, Vallon V: Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens 2016;25:50-58.
18. Vallon V, Thomson SC: Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 2017;60:215-225.
19. Panchapakesan U, Pegg K, Gross S, et al.: Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 2013;8:e54442.
20. Heerspink HJ, Desai M, Jardine M, et al.: Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017;28:368-375.
21. Neal B, Perkovic V, Mahaffey KW, et al.: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657.
22. Witte EC, Lambers Heerspink HJ, de Zeeuw D, et al.: First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009;20:436-443.
23. Matsuo S, Imai E, Horio M, et al.: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.
24. Horio M, Imai E, Yasuda Y, et al.: GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis 2013;61:197-203.
25. de Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110: 921-927.
26. Japanese Society of Nephrology: Evidence-based clinical practice guideline for CKD 2013. Chapter 9: diabetic nephrology. Clin Exp Nephrol 2014;18:370-374.
27. American Diabetes Association: 3. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41: S28-S37.
28. Cherney D, Lund SS, Perkins BA, et al.: The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 2016;59:1860-1870.
29. Heerspink HJ, Johnsson E, Gause-Nilsson I, et al.: Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 2016;18:590-597.
30. Petrykiv SI, Laverman GD, de Zeeuw D, Heerspink HJL: The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients. Diabetes Obes Metab 2017;19:1363-1370.
31. Howard RL, Buddington B, Alfrey AC: Urinary albumin, transferrin and iron excretion in diabetic patients. Kidney Int 1991;40:923-926.
32. Thomas MC, Burns WC, Cooper ME: Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 2005; 12:177-186.
33. Tang SC, Lai KN: The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol Dial Transplant 2012;27:3049-3056.
34. Ferrannini E, Mark M, Mayoux E: CV Protection in the EMPA-REG OUTCOME Trial: a ''Thrifty Substrate'' Hypothesis. Diabetes Care 2016;39:1108-1114.
35. Sano M, Takei M, Shiraishi Y, Suzuki Y: Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 2016;8:844-847.
36. Mudaliar S, Alloju S, Henry RR: Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 2016;39:1115-1122.
37. Cherney DZ, Perkins BA, Soleymanlou N, et al.: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597.
38. Lambers Heerspink HJ, de Zeeuw D, Wie L, et al.: Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013;15:853-862.
39. Wanner C, Inzucchi SE, Lachin JM, et al.: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334.
40. Apperloo AJ, de Zeeuw D, de Jong PE: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793-797.
41. Holtkamp FA, de Zeeuw D, Thomas MC, et al.: An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011;80:282-287.
42. Morales E, Millet VG, Rojas-Rivera J, et al.: Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant 2013;28:405-412.
43. Zatz R, Dunn BR, Meyer TW, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77: 1925-1930.
44. Heerspink HJ, Perkins BA, Fitchett DH, et al.: Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134:752-772.
45. Yamagishi S, Matsui T: Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010;3:101-108.
46. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J: Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011;7:327-340.
47. Yamout H, Perkovic V, Davies M, et al.: Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 2014;40:64-74.
48. Hahn K, Ejaz AA, Kanbay M, et al.: Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 2016;12:711-712.
49. Szalat A, Perlman A, Muszkat M, et al.: Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf 2018;41:239-252.